Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens
Recent studies have shown the importance of triggering CD40 molecules to enhance the efficiency of d...
Adequate spontaneous activation of tumor-specific T lymphocytes in tumor-bearing hosts is rare, desp...
Background: Agonistic CD40 antibodies have been demonstrated to activate antigen-presenting cells (A...
Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate an...
Introduction: CD40 signaling activates dendritic cells leading to improved T cell priming against tu...
The introduction of checkpoint inhibitors represents a major advance in cancer immunotherapy. Some s...
BACKGROUND: Stimulation of CD40 can augment anti-cancer T cell immune responses by triggering effect...
Tumor-targeted CD40 agonism represents an attractive strategy for cancer immunotherapy (CIT) as it p...
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction ...
CD40 is a costimulatory molecule widely expressed by immune cells and by neoplastic cells of differe...
Overcoming dendritic cell (DC) dysfunction is a prerequisite for successful active immunotherapy aga...
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment including c...
SummaryCancer immunotherapies are more effective in tumors with robust T cell infiltrates, but mecha...
Cancer immunotherapies are more effective in tumors with robust T cell infiltrates, but mechanisms t...
Cancer, historically considered a genetic disease, is currently acknowledged to affect the whole bod...
Recent studies have shown the importance of triggering CD40 molecules to enhance the efficiency of d...
Adequate spontaneous activation of tumor-specific T lymphocytes in tumor-bearing hosts is rare, desp...
Background: Agonistic CD40 antibodies have been demonstrated to activate antigen-presenting cells (A...
Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate an...
Introduction: CD40 signaling activates dendritic cells leading to improved T cell priming against tu...
The introduction of checkpoint inhibitors represents a major advance in cancer immunotherapy. Some s...
BACKGROUND: Stimulation of CD40 can augment anti-cancer T cell immune responses by triggering effect...
Tumor-targeted CD40 agonism represents an attractive strategy for cancer immunotherapy (CIT) as it p...
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction ...
CD40 is a costimulatory molecule widely expressed by immune cells and by neoplastic cells of differe...
Overcoming dendritic cell (DC) dysfunction is a prerequisite for successful active immunotherapy aga...
Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment including c...
SummaryCancer immunotherapies are more effective in tumors with robust T cell infiltrates, but mecha...
Cancer immunotherapies are more effective in tumors with robust T cell infiltrates, but mechanisms t...
Cancer, historically considered a genetic disease, is currently acknowledged to affect the whole bod...
Recent studies have shown the importance of triggering CD40 molecules to enhance the efficiency of d...
Adequate spontaneous activation of tumor-specific T lymphocytes in tumor-bearing hosts is rare, desp...
Background: Agonistic CD40 antibodies have been demonstrated to activate antigen-presenting cells (A...
DOI
Add to ORKG